Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany  by Korn, S. et al.
Respiratory Medicine (2009) 103, 1725e1731ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedOmalizumab in patients with severe persistent
allergic asthma in a real-life setting in GermanyS. Korn a, A. Thielen b, S. Seyfried b, C. Taube a, O. Kornmann a, R. Buhl a,*a Pulmonary Dept., Mainz University Hospital, Langenbeckstr. 1, 55131 Mainz, Germany
b Novartis Pharma GmbH, Roonstr. 25, 90429 Nuremberg, Germany
Received 31 March 2009; accepted 2 May 2009
Available online 9 June 2009KEYWORDS
Asthma;
IgE;
Omalizumab;
Allergy;
Therapy* Corresponding author. Tel.: þ49 61
5545.
E-mail address: r.buhl@3-med.klin
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.05.002Summary
Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Eur-
ope for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite
optimal therapy with inhaled corticosteroids and long-acting b2 agonists.
Between 2005 and 2007 280 patients (58% female, mean age 44 16 yrs., 46% on oral corti-
costeroids, median serum IgE level 235 IU/ml) who met the EU criteria for add-on therapy with
anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-
marketing surveillance trial and were followed-up for 6 months.
The median follow-up time was 195 days, the patients were treated with a median dose of
450 mg omalizumab every 4 weeks. After 6 months there was a marked effect of omalizumab
treatment on daily (76%) and nocturnal symptoms (84%), exacerbations (82%), unsched-
uled health care contacts (81%), hospitalizations (78%) and quality of life (Mini-AQLQ: score
increase from 2.9 to 4.5). Overall, efficacy of omalizumab was rated as excellent or good by
the majority of physicians (82%) and patients (86%). In 19 patients (7%) omalizumab-related
adverse events were recorded.
This post-marketing surveillance trial confirms the marked and clinically relevant effect of
omalizumab on asthma symptoms and level of asthma control in the majority of patients with
severe persistent allergic (IgE-mediated) asthma in a real-life situation.
ª 2009 Elsevier Ltd. All rights reserved.31 17 7270; fax: þ49 6131 17
ik.uni-mainz.de (R. Buhl).
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Asthma represents one of the most common chronic
diseases.1,2 In the majority of patients control of asthma as
defined by guidelines can be achieved with inhaled corti-
costeroids and b2-agonists.3e5 However, patients with
severe persistent asthma who are inadequately controlled
despite treatment according to current asthma guidelines.
1726 S. Korn et al.are at high risk of severe exacerbations and asthma-related
mortality and represent the greatest unmet medical need
among the asthmatic population today.6,7
Recently, the recombinant humanized monoclonal anti-
immunoglobulin E (IgE) antibody omalizumab has been
introduced as an add-on treatment for patients with inad-
equately controlled persistent allergic asthma despite GINA
step 5 therapy. IgE plays a central role in the pathogenesis
of allergic asthma.8 After sensitization, atopic patients
respond to allergen exposure through a number of IgE-
dependent mechanisms,8 making IgE a novel and attractive
target for anti-allergic and anti-asthmatic treatments.9
Omalizumab interrupts the allergic cascade by binding free
serum IgE.10 Clinical trials confirm that in patients with
allergic asthma who have a significant unmet need despite
best available therapy omalizumab as add-on therapy
reduced asthma symptoms, clinically significant asthma
exacerbations and emergency visits as well as hospitaliza-
tions due to asthma.8,9,11e17
In 2005, omalizumab has been approved by the European
Medicines Agency (EMEA) as add-on therapy for patients 12
years and older with severe persistent allergic asthma who
demonstrate a positive skin prick test or an in vitro reac-
tivity to a perennial aeroallergen, a reduction in lung
function (FEV1< 80%), frequent daily symptoms or nightly
awakenings, multiple severe asthma exacerbations despite
treatment with high doses of inhaled corticosteroids and
long-acting-b2 agonists, and a treatable IgE burden as
defined by total serum IgE and body weight within the
therapeutic window.
Aim of the present prospective post-marketing surveil-
lance trial was to verify the efficacy and tolerability of
omalizumab in a real-life setting following the introduction
of the drug to the German market in October 2005. It
describes the characteristics of patients and the real-life
effectiveness of omalizumab in the first large group of
patients who received this treatment in Germany.
Methods
Patients
This observational study was performed according to Good
Clinical Practice (GCP) standards, the declaration of Hel-
sinki and was approved by the local ethics committee. All
patients included in this study gave written informed
consent.
In the period between November 2005 and February
2007 280 patients with uncontrolled severe persistent
allergic asthma were treated with omalizumab and were
prospectively investigated by 135 physicians in Germany.
Patients were selected for add-on therapy with omalizumab
as approved by the EMEA and as recommended by German18
and international guidelines2 based on age (patients 12
years), positive skin prick test or in vitro reactivity against
at least one perennial allergen, reduced lung function
(FEV1< 80% pred.), frequent daily symptoms or nocturnal
awakenings, severe asthma exacerbations despite high
doses of inhaled corticosteroids and long-acting b2-
agonists, total serum IgE between 30 and 700 IE/ml, and
body weight between 20 and 150 kg.Study design
Due to its mechanism of action, the EMEA recommends that
omalizumab treatment effectiveness be assessed after 16
weeks of treatment.19 Consequently, patients were investi-
gated prior to start of treatment with omalizumab as well as
after 4 and 6months of the treatment phase. At the initial visit
physicians completed a questionnaire regarding the 12month-
period prior to omalizumab treatment (baseline data) to
collect demographics (date of birth, sex, smoking status),
abnormal pulmonary function defined as an FEV1< 80% of
predicted, asthma-related treatments (inhaled corticoste-
roids, long-acting b2-agonists, oral corticosteroids, sustained-
release theophylline, leukotriene receptor antagonists), daily
symptoms, nightly awakenings, days off school or work,
number ofexacerbations (as definedbyFEV1< 60%of personal
best, intermittent treatment with oral corticosteroids,
unscheduled health care visits, emergency treatments,
hospitalizations due toasthma), hospitalizations, unscheduled
health care visits, and omalizumab dosing information (body
weight of patient, total IgE). Quality of life (QoL) was assessed
using theMini AdultAsthmaQuality of LifeQuestionnaire (Mini-
AQLQ).20 The quality of life score was calculated using the
following equation: total scoreZ total (question 1equestion
10)/number (question 1equestion 10). Both patients and
investigators independently evaluated treatment effective-
ness and tolerability of omalizumab after 4 and 6 months.
4 and 6 months after the start of omalizumab treatment
physicians completed questionnaires providing information
about treatment discontinuation (date, reason), date of last
clinical evaluation whilst still under treatment, modifica-
tion of asthma-related treatments (inhaled corticosteroids,
long-acting b2-agonists, oral corticosteroids, slow-release
theophylline, leukotriene receptor antagonists), daily
asthma symptoms/nocturnal awakenings, and adverse
events suspected to be linked to omalizumab treatment.
Lung function changes were recorded as categorical vari-
ables, i.e. improved or deteriorated compared with base-
line. At the end of the trial period after 6 months patients
again provided information about days off school or work,
and the number of exacerbations. As is typical for post-
marketing surveillance trials and to reflect the real-life-
situation in daily clinical routine instructions concerning
diagnostic and therapeutic procedures were not issued.
Medication and dosing
Individual omalizumab doses were calculated according to
a dosing table based on the patient’s individual IgE load,
i.e. on pre-treatment body weight and total serum IgE level
at screening, as previously described.21 Depending on the
omalizumab dose, the drug was administered by subcuta-
neous injection every 2 or 4 weeks. There were no
restrictions on doses of ICS and LABA (taken separately or as
a fixed combination) and other concomitant asthma medi-
cations during the treatment period.
Statistical analysis
In the study population, effectiveness of omalizumab over
the treatment period as reflected by the reduction of
Omalizumab in real life 1727exacerbations was evaluated in all patients with follow-up
data. Analyses were descriptive and annual rates calcu-
lated using patient-years. All patients treated with omali-
zumab at least once were considered for tolerability
evaluation by monitoring of adverse events. Due to the
observational character of the study neither a primary
endpoint was defined nor a statistical power calculation
was performed. Data analysis was performed by using SAS
software. Data description was primarily based on means
and standard deviation or medians and quartiles for
continuous endpoints and based on frequencies for cate-
gorical endpoints. The resulting pair wise comparisons were
based on Wilcoxon test or t test and on Fishers exact test (p
values< 0.05 indicate local statistical significance).
Results
Study population
During the period between November 2005 and February
2007, 280 patients with physician-diagnosed severe persis-
tent allergic asthma with a mean age of 43.9 16.3 years
(range 10e78 years, 3 patients 12 years) were followed up
for a mean of 195 60 days (Table 1). All patients had
a documented sensitization to at least one perennial aer-
oallergen. 243 patients (86.8%) suffered from additional
allergic diseases. Accordingly, in 226 patients (80.0%)
attempts were made to reduce allergen exposure (e.g.
mattress covers in 75.2% of patients). The median IgE level
prior to treatment with omalizumab was 235.0 IU/mlTable 1 Study population.
Patients
Sex [female]
Smoking status [non-smokers, ex-smokers, still smokers]
Additional allergic diseases
Allergic rhinitis/rhinoconjunctivitis
Atopic dermatitis
Food allergy
Other
Sensitization to allergens
Mites
Animal dander
Molds
Grass pollen
Birch
Other
Asthma medication
High doses
of inhaled corticosteroids
Long-acting beta-2-agonists
Combination therapy
(inhaled corticosteroids and beta-2-agonists)
Slow-release theophylline
Leukotriene receptor antagonists
Oral corticosteroids
(as maintenance therapy)(interquartile range 130e457 IU/ml, min. 16 IU/ml, max.
5820 IU/ml), mean body weight was 73.1 17.2 kg (range
27e150 kg). All patients were treated with high doses of
inhaled corticosteroids and long-acting b2-agonists. The
majority of patients (90.4%) were treated by at least 2 and
upto 7 different classes of drugs. In retrospect 271 patients
(96.8%) fulfilled the criteria for severe allergic asthma
according to the omalizumab label (Table 1).
Pre-treatment asthma control
In the 12 months prior to initiation of omalizumab treat-
ment 269 patients (96.1%) reported daily asthma symptoms
and 242 patients (86.4%) nightly awakenings. Nearly all
patients (90.0%) had experienced frequent severe asthma
exacerbations (mean 4.5 7.5 exacerbations/year), 67
patients (23.9%) were hospitalized due to exacerbations. In
addition, 238 patients (85.0%) reported on average
4.4 4.6 unscheduled health care contacts or emergency
room visits due to asthma in the year prior to treatment
with omalizumab. 171 patients (61.1%) had not been able to
go to work or school for at least one day. Total pre-treat-
ment quality of life score was 2.9 0.9 points (Table 2).
Asthma control after 4 and 6 months
of omalizumab treatment
Patients were administered a median of 450 mg omalizu-
mab per month (range 150e850 mg per month). In 43
patients (14.9%) the IgE load was outside the recommendedn [patients] % Of patients
280
114 40.7
209, 40, 13 79.8, 15.3, 4.9
243 86.8
228 93.8
84 34.6
77 31.7
18 7.4
280 100
219 78.2
182 65.0
132 47.1
201 71.8
191 68.2
68 24.3
142 50.7
124 44.3
166 59.3
122 43.6
136 48.6
129 46.1
To worry about something
Wheezing
Cough
Table 2 Results.
Baseline [nZ 280]a After 4 months [nZ 279]a After 6 months [nZ 241]a
n [patients] % Of patients n [patients] % Of patients n [patients] % Of patients
Daily asthma symptoms 269 96.1 83 29.7 55 22.8
Nightly awakenings 242 86.4 67 24.0 33 13.7
Asthma exacerbations 252 90.0 e e 44 18.3
Hospitalizations 67 23.9 e e 12 2.5
Unscheduled health
care contacts/emergency room visits
238 85.0 e e 48 19.9
Days off school/work 171 61.1 e e 40 16.6
a Due to the observational character of the study not all information are available in a small number of patients.
1728 S. Korn et al.dosing table, either because total serum IgE was too low or
too high and/or body weight was too low or too high.
Upon reevaluation of patients after 4 months there was
a marked reduction of daily asthma symptoms and
nocturnal awakenings by 69.1% and 72.3% resp. (p< 0.001
resp.). After 6 months there was a further reduction in daily
symptoms and nocturnal awakenings down to a total
reduction of 79.6% and 86.4% resp. (p< 0.001 resp.). During
therapy with omalizumab concomitant allergy manifesta-
tions decreased significantly by 80.6% after 4 months and by
87.1% after 6 months (p< 0.001, both comparisons). In 177
patients (63.4%) lung function improved after 4 months and
in 157 of 241 patients (65.1%) after 6 months. Compared
with the 12 month pre-treatment period the rate of severe
asthma exacerbations decreased by 82.0% to a mean of
0.3 0.8 exacerbations/year (rate adjusted to a 1-year
period; p< 0.001). During the whole follow-up period of 6
months 12 patients (5.0%) were hospitalized due to exac-
erbations, corresponding to a reduction of 77.5%
(p< 0.001). Similarly, unscheduled health care visits and
emergency room visits decreased by 80.8% (p< 0.001).
Total days patients were not able to go to work or to school
were reduced by 71.6% (p< 0.001) (Fig. 1). Accordingly,
there was a marked improvement in quality of life. Mean
total score increased to 4.5 1.2 points (p< 0.001) (Fig. 2).
After 6 months efficacy and tolerability of omalizumab
was rated as excellent or good by the majority of physicians
(82.2% and 95.0%) and patients (85.9% and 93.7%) (Table 2).
Tolerability and discontinuations
In 100 patients (35.7%) a total of 198 adverse events and in
67 patients (23.9%) a total of 145 severe adverse events-100
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Figure 1 Effects [%] of omalizumab after 6 months of
treatment compared with baseline.(73.2%) were reported. In only 7 of all patients (2.5%) 33
adverse events (16.7% of all AEs) were considered to be
related to omalizumab treatment (Table 3).
As expected, the respiratory system (37.6%) was the
organ system most commonly affected by adverse events,
with ‘‘asthma’’ being the leading complaint (65 patients).
47 patients (16.8%) discontinued omalizumab treatment
after 4 months and 44 patients (18.3%) after 6 months,
corresponding to a total discontinuation rate of 32.5%. Main
reason for discontinuation was ineffectiveness (48.9% after
4 months, 38.6% after 6 months). Due to the small numbers
of patients who discontinued treatment no statistical
analyses could be performed to relate insufficient treat-
ment response to a potential overdosing or underdosing of
the study drug.
Discussion
Omalizumab has been successfully adopted into clinical
practice, with more than 68,000 patients treated world-
wide since June 2003. Clinical trials have shown important
benefits for many patients with inadequately controlled
severe persistent allergic asthma who respond to omalizu-
mab therapy, and demonstrated a good safety profile. This
supports the results from the comprehensive clinical trial
programme, in which omalizumab significantly reduced
asthma exacerbation and emergency visit rates, and
significantly improved quality of life in patients with severe0 20 40 60 80 100
Shortness of breath
Avoiding dust
Frustration
Chest tightness
Worries about asthma medication
Exposure to cigarette smoke
Sleep disorders
% of patients
After 6 months of omalizumab1 year prior to omalizumab
Figure 2 Mini AQLQ, 7 point score (1Z always, 2Zmostly,
3Z often, 4Z sometimes, 5Z rarely, 6Z hardly ever,
7Z never). Bars represent points 1e3.
Table 3 Adverse events.
Adverse events n [patients] % Of patients n [adverse events] % Of adverse events
Total adverse events 100 35.7 198 100.0
Total severe
adverse events
67 23.9 145 73.2
Severe adverse
event related to omalizumab
7 2.5 33 16.7
Organ systems
most commonly affected
by adverse events
(multiple response)
Respiratory, thoracic
and mediastinal disorders
67 23.9 73 37.6
General disorders
and administrations site conditions
40 14.3 48 24.7
Infections and infestations 14 5.0 14 7.2
Nervous system disorders 8 2.9 17 8.8
Skin and subcutaneous
tissue disorders
7 2.5 10 5.2
Omalizumab in real life 1729persistent allergic asthma. Pooled analyses confirm the
results of the omalizumab clinical trial program.9,17
Consequently, omalizumab is indicated in the EU as add-on
therapy to improve control of severe persistent allergic
asthma that remains inadequately controlled despite
treatment with high-dose ICS and a LABA.
The present study summarizes the clinical experience
with omalizumab in a large cohort of German patients with
severe allergic asthma following the approval of the drug
within the European Union and its launch in Germany. It is
the first analysis of the therapeutic effects of omalizumab
in a real-life setting in Germany outside of clinical trials.
Several aspects of this study are clinically relevant:
In contrast to the controlled trials performed as part of
the omalizumab clinical trial program patient recruitment
into the present study was not based on in e and exclusion
criteria derived from study hypotheses. The patients
included in this trail were selected according to the
approved European omalizumab label, and, with very few
exceptions, the patients’ characteristics are well in line
with the criteria recommended for the use of omalizumab
by the European Medicines Agency (EMEA).19 This is
reflected in the study population by the mean daily dose of
inhaled corticosteroids and the high rate of asthma-related
events in the year preceding omalizumab treatment. In
particular the high rate of exacerbations including emer-
gency visits and hospitalizations highlights the fact that
asthma in these patients was uncontrolled despite their
already high use of anti-asthmatic medication. Further, the
study population reflects both the huge unmet clinical
need in patients with severe allergic asthma uncontrolled
by guideline-based treatment2,22 and the potential for
improvement following the institution of guideline-based
treatment including omalizumab. Importantly, almost half
of the study population was on oral maintenance cortico-
steroids, an exclusion criterion for most of the phase III
omalizumab trials. The results of this trial indicate and
confirm preliminary evidence that omalizumab is effective
in severe persistent allergic asthma irrespective ofconcomitant treatment with systemic corticosteroids.17
Omalizumab can, therefore, be considered for the treat-
ment of inadequately controlled severe persistent allergic
asthma, regardless of OCS use.
This was a real-life study reflecting daily clinical prac-
tice in an outpatient setting typical for the situation in
Germany. In some aspects, the extent of clinical improve-
ment experienced by the majority of patients following
treatment with omalizumab was even more pronounced
than what was observed in controlled clinical trials.11,17
Results similar to what was seen in the German cohort were
observed in a comparable situation in France.23 It is
tempting to speculate that controlled studies potentially
underestimate the omalizumab effect and overestimate
the effects of standard treatment in placebo or comparator
arms due to high adherence and expert guidance that is
inherent to controlled trials. In a real-life setting adher-
ence in particular to inhaled corticosteroids is notoriously
poor24 while monthly injections that can be scheduled
according to the patients’ individual needs may favor
treatment adherence. The pronounced effect on the rate
of severe asthma-related events including hospitalizations
is equally relevant in the context of the ongoing discussion
about the costeeffectiveness of omalizumab.25 However,
a detailed analysis of cost and effectiveness of this new
treatment was beyond the scope of this investigation.
A French historic-prospective study has provided initial
data on the real-world effectiveness of omalizumab. In the
French study, the annual exacerbation rate decreased by
62%, emergency visits by 65% and hospitalizations by 29%
for the 146 patients who had been prescribed omalizumab
for severe allergic asthma. Additionally, 48.1% of patients
reduced or discontinued maintenance OCS.23
Analyses of patients treated in clinical trials have shown
that it is difficult to predict which patients, within the label
population, will derive greatest benefit from omalizumab
based on pre-treatment patient characteristics. As recom-
mended in the EU, the most accurate means of ensuring
that omalizumab treatment is beneficial to evaluate the
1730 S. Korn et al.response after a 16-week therapeutic trial. Treatment
should be continued in patients who are judged by the
physician to have achieved a marked improvement or
complete asthma control. Using this method of assessment,
approximately 60% of patients can be expected to be
identified as responders to omalizumab. The reason why
not all patients respond to omalizumab therapy is
unclear.26 Well in line with this experience, 32.5% of
patients treated in the present study discontinued omali-
zumab treatment, mostly due to unsatisfactory therapeutic
response. As was seen in the French trial, incorrect dosing
may contribute to an insufficient response to the drug.23 In
our cohort, 14.9% of patients who were treated did not fall
within the range of the recommended dosing table that
considers total IgE concentration and body weight.27
Potentially, both over-treatment and under-treatment may
be explained by the design of the present study which was
close to a post-marketing surveillance to give flexibility to
the prescriber. However, the small number of patients who
discontinued treatment or were incorrectly dosed
precluded any statistical analyses to relate insufficient
treatment response to a potential overdosing or under-
dosing of the study drug. Although the potential relation-
ship between under treatment and unsatisfactory
therapeutic response could have been formally strength-
ened at inclusion and follow-up visits, such as an inter-
vention could have modified prescriber behavior and
compromise the real-life nature of the study. It is, there-
fore, essential that the correct dose of omalizumab is
calculated and administered for each individual patient.
Finally, the present trial confirmed the favorable safety
profile of omalizumab. Frequency and severity of adverse
events observed were similar to that seen in the omalizu-
mab phases II and III study program and in many respects
comparable to what was reported by patients receiving
placebo or best available therapy.28
This study has several limitations. Clearly, its results
strongly suggest that the clinical efficacy of omalizumab
demonstrated in randomized controlled trials (RCTs) is
reproduced in a real-life setting. The magnitude of the
improvements seen when compared with the previous year
was at least comparable to that observed in RCTs. However,
the results of this trial are based on retrospective
comparisons within the same patient population instead of
a comparison with a control group or a prospectively
defined baseline period. Furthermore, confounding factors
such as the placebo effect or a more strict compliance to
existing medications due to more frequent physician
contacts could not be taken into account. Nevertheless,
prescribing practices participating in this trial are repre-
sentative of the German situation and thus reflect real-life
conditions of use.
Another limitation of the study is the way study centers
and patients were recruited. In principle, participation in
this trial was offered to all German pulmonary and allergy
specialists. Neither study centers nor patients fulfill the
criteria of a random German sample but represent a selec-
tion of physicians who agreed to participate in this trial and
who included as many patients as they thought were
appropriate. Again, however, the large number of patients
makes this sample in many respects representative for the
German situation.Conclusion
In summary, in a German 6-month real-life follow-up study
conducted between 2005 and 2007 treatment of 280
patients with severe persistent allergic asthma uncon-
trolled by inhaled corticosteroids and long-acting b2-
agonists with omalizumab were generally well tolerated
and reduced daily and nocturnal symptoms, asthma exac-
erbation and emergency visit rates, and improved quality of
life. Treatment efficacy was rated as excellent or good by
the majority of both physicians and patients, thus con-
firming the clinically relevant effect of omalizumab.
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